CD8A and neoplasm: Research has shown that lenvatinib modulates cancer immunity in the immunocompetent tumor microenvironment by reducing the population of tumor-associated macrophages (TAMs) and increasing the population of interferon-γ– and granzyme-B–producing CD8+ T cells [30, 31].